| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | U59UGK3IPC |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| BINDING AGENT | B-lymphocyte antigen CD20 binding agent |
| Primary Target | |
|---|---|
| CD20 (membrane-spanning 4-domains, subfamily A, member 1) |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Multiple Sclerosis, Chronic Progressive | 4 | D020528 | FDA |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | D015451 | ClinicalTrials |
| Multiple Sclerosis | 3 | D009103 | ClinicalTrials |
| Lymphoma, Follicular | 2 | D008224 | ClinicalTrials |
| Lymphoma, Large B-Cell, Diffuse | 2 | D016403 | ClinicalTrials |
| Lymphoma, Mantle-Cell | 2 | D020522 | ClinicalTrials |
| Lymphoma, Follicular | 2 | D008224 | ClinicalTrials |
| Lymphoma, Non-Hodgkin | 1 | D008228 | ClinicalTrials |
| Waldenstrom Macroglobulinemia | 1 | D008258 | ClinicalTrials |
| Neuromyelitis Optica | 1 | D009471 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1174014-05-1 |
| ChEMBL | CHEMBL2108354 |
| FDA SRS | U59UGK3IPC |
| Guide to Pharmacology | 8920 |
CONTENTS